Isothiazolones interfere with normal matrix metalloproteinase activation and inhibit cartilage proteoglycan degradation

被引:8
作者
Arner, EC
Pratta, MA
Freimark, B
Lischwe, M
Trzaskos, JM
Magolda, RL
Wright, SW
机构
[1] Inflammatory Diseases Research, DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington
关键词
D O I
10.1042/bj3180417
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of isothiazolones that inhibit pro-(matrix metalloproteinase) (proMMP) activation but do not inhibit the active enzyme are effective as cartilage protectants in bovine nasal cartilage organ culture, preventing interleukin-1 (IL-1)-induced proteoglycan (aggrecan) degradation without affecting its synthesis. These compounds were found to bind to prostromelysin (proMMP-3) in a non-dialysable and stoichiometric manner. Preincubation with cartilage-protectant isothiazolones prevented the binding of [C-14]iodoacetamide to Cys(75) Of the MMP-3 propeptide, suggesting that the activity of these compounds involves their binding to the Cys(75) of the MMP zymogen. Studies following chymotrypsin activation of proMMP-3 by SDS/PAGE indicated that altered processing of the 57 kDa zymogen to the active form occurred in the presence of compound. The 53 kDa intermediate seen on normal activation was not formed; instead a different intermediate appeared with a molecular mass of approx. 46 kDa. N-terminal sequence analysis indicated that this intermediate was formed by cleavage at the putative 4-aminophenylmercuric acid cleavage site. Importantly the 45 kDa active MMP-3 species formed in the presence of compound was one amino acid residue shorter than the native MMP-3. These results suggest that the inhibition of cartilage proteoglycan degradation by isothiazolones might be due to their ability to bind to the Cys(75) in the propeptide region of the MMP zymogen and interfere with its normal activation process.
引用
收藏
页码:417 / 424
页数:8
相关论文
共 46 条
[1]  
AMER EC, 1989, ARTHRITIS RHEUM, V32, P288
[2]  
AMER EC, 1991, ARTHRITIS RHEUM, V34, P1006
[3]   INVIVO STUDIES ON THE EFFECTS OF HUMAN RECOMBINANT INTERLEUKIN-1-BETA ON ARTICULAR-CARTILAGE [J].
ARNER, EC ;
DIMEO, TM ;
RUHL, DM ;
PRATTA, MA .
AGENTS AND ACTIONS, 1989, 27 (3-4) :254-257
[4]  
BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140
[5]   INHIBITION OF CARTILAGE PROTEOGLYCAN RELEASE BY A SPECIFIC INACTIVATOR OF CATHEPSIN-B AND AN INHIBITOR OF MATRIX METALLOPROTEINASES - EVIDENCE FOR 2 CONVERGING PATHWAYS OF CHONDROCYTE-MEDIATED PROTEOGLYCAN DEGRADATION [J].
BUTTLE, DJ ;
HANDLEY, CJ ;
ILIC, MZ ;
SAKLATVALA, J ;
MURATA, M ;
BARRETT, AJ .
ARTHRITIS AND RHEUMATISM, 1993, 36 (12) :1709-1717
[6]  
CAPUTO CB, 1987, J PHARMACOL EXP THER, V240, P460
[7]   DISRUPTION OF THE CYSTEINE-75 AND ZINC ION COORDINATION IS NOT SUFFICIENT TO ACTIVATE THE PRECURSOR OF HUMAN MATRIX METALLOPROTEINASE-3 (STROMELYSIN-1) [J].
CHEN, LC ;
NOELKEN, ME ;
NAGASE, H .
BIOCHEMISTRY, 1993, 32 (39) :10289-10295
[8]  
CHIN JR, 1985, J BIOL CHEM, V260, P2367
[9]   A DIRECT SPECTROPHOTOMETRIC MICRO-ASSAY FOR SULFATED GLYCOSAMINOGLYCANS IN CARTILAGE CULTURES [J].
FARNDALE, RW ;
SAYERS, CA ;
BARRETT, AJ .
CONNECTIVE TISSUE RESEARCH, 1982, 9 (04) :247-248
[10]  
FOSANG AJ, 1992, J BIOL CHEM, V267, P19470